CHF46.80
1.37% today
SIX Swiss Exchange, Aug 25, 11:16 am CET
ISIN
CH0011432447
Symbol
BSLN

Basilea Pharmaceutica Stock price

CHF47.45
-6.45 11.97% 1M
+1.50 3.26% 6M
+6.10 14.75% YTD
+2.55 5.68% 1Y
+8.65 22.29% 3Y
-6.50 12.05% 5Y
-46.80 49.66% 10Y
-54.55 53.48% 20Y
SIX Swiss Exchange, Closing price Fri, Aug 22 2025
-0.05 0.11%
ISIN
CH0011432447
Symbol
BSLN
Industry

Key metrics

Basic
Market capitalization
CHF578.5m
Enterprise Value
CHF532.1m
Net debt
positive
Cash
CHF128.4m
Shares outstanding
12.3m
Valuation (TTM | estimate)
P/E
9.1 | 11.2
P/S
2.4 | 2.6
EV/Sales
2.3 | 2.4
EV/FCF
6.8
P/B
5.6
Financial Health
Equity Ratio
31.4%
Return on Equity
95.8%
ROCE
35.4%
ROIC
72.4%
Debt/Equity
0.8
Financials (TTM | estimate)
Revenue
CHF236.2m | CHF222.3m
EBITDA
CHF77.8m | CHF57.7m
EBIT
CHF76.0m | CHF58.4m
Net Income
CHF72.7m | CHF52.0m
Free Cash Flow
CHF77.8m
Growth (TTM | estimate)
Revenue
58.5% | 6.6%
EBITDA
1,246.2% | -8.2%
EBIT
1,000.2% | -4.6%
Net Income
11,278.5% | -33.0%
Free Cash Flow
751.3%
Margin (TTM | estimate)
Gross
81.0%
EBITDA
33.0% | 26.0%
EBIT
32.2%
Net
30.8% | 23.4%
Free Cash Flow
32.9%
More
EPS
CHF5.2
FCF per Share
CHF6.3
Short interest
-
Employees
164
Rev per Employee
CHF1.3m
Show more

Is Basilea Pharmaceutica a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

Basilea Pharmaceutica Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Basilea Pharmaceutica forecast:

9x Buy
82%
2x Hold
18%

Analyst Opinions

11 Analysts have issued a Basilea Pharmaceutica forecast:

Buy
82%
Hold
18%

Financial data from Basilea Pharmaceutica

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
236 236
59% 59%
100%
- Direct Costs 45 45
28% 28%
19%
191 191
68% 68%
81%
- Selling and Administrative Expenses 34 34
3% 3%
14%
- Research and Development Expense 82 82
9% 9%
35%
78 78
1,246% 1,246%
33%
- Depreciation and Amortization 1.87 1.87
13% 13%
1%
EBIT (Operating Income) EBIT 76 76
1,000% 1,000%
32%
Net Profit 73 73
11,278% 11,278%
31%

In millions CHF.

Don't miss a Thing! We will send you all news about Basilea Pharmaceutica directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. Its products include antifungals and antibiotics. The company was founded on October 17, 2000, and is headquartered in Allschwil, Switzerland.

Head office Switzerland
CEO David Veitch
Employees 164
Founded 2000
Website www.basilea.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today